It was announced yesterday that Bapineuzumab, the Abeta immunotherapy drug, failed to meet cognitive and functional goals in a late stage trial of Alzheimer’s patients who carry the APOE4 variant. “There was no reason to believe, unless there was a miracle, that this would be positive. It will only be the results of the non-APOE4 carriers that will inform us about the future [of bapineuzumab].” said Rudolph Tanzi, Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School and MGH in Boston and Chair of the Cure Alzheimer’s Research Consortium.
The story is reported in the following articles:
Wall Street Journal:
Bloomberg:
Other articles:
NYT (quoting Sam Gandy):
Associated Press:
